1 |
Waller, C. F., Bronchud, M., Mair, S. and Challand, R. (2010a). Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: Results from a randomized, phase I trial, Annals of Hematology, 89, 927-933.
DOI
|
2 |
Waller, C. F., Bronchud, M., Mair, S. and Challand, R. (2010b). Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: Results from a randomized, phase I trial, Annals of Hematology, 89, 971-978.
DOI
|
3 |
Waller, C. F., Semiglazov, V. F., Tjulandin, S., Bentsion, D., Chan, S. and Challand, R. (2010c). A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer, Onkologie, 33, 504-511.
|
4 |
Wellek, S. (2003). Testing Statistical Hypotheses of Equivalence, Chapman & Hall/CRC, London.
|
5 |
U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2003). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville MD 20857.
|
6 |
EMEA Committee for Medicinal Products for Human Use. (2010). Guideline on the Investigation of Bioequivalence, CPMP/EWP/QWP/1401/98 Rev. 1. London.
|
7 |
Gatzemeier, U., Ciuleanu, T., Dediu, M., Ganea-Motan, E., Lubenau, H. and Del Giglio, A. (2009). XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy, Journal of Thoracic Oncology, 4, 736-740.
DOI
ScienceOn
|
8 |
Hauschke, D., Steinijas, V. and Pigeot, I. (2007). Bioequivalence Studies in Drug Development: Methods and Applications, John Wiley & Sons, New York.
|
9 |
Lubenau, H., Bias, P., Maly, A., Siegler, K. E. and Mehltretter, K. (2009). Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim neupogen: Single-blind, randomized, crossover trial, Biodrugs, 23, 43-51.
DOI
ScienceOn
|
10 |
Newcombe, R. G. (1988). Interval estimation for the difference between independent proportions: Comparison of eleven methods, Statistics in Medicine, 17, 873-890.
|
11 |
Patterson, S. and Jones, B. (2006). Bioequivalence and Statistics in Clinical Pharmacology, Chapman & Hall/CRC, London.
|
12 |
Schellekens, H. (2004). How similar do 'biosimilars' need to be?, Nature Biotechnology, 22, 1357-1359.
DOI
ScienceOn
|
13 |
Schuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailabilty, Journal of Pharmacokinetics and Biophamaceutics, 15, 657-680.
DOI
|
14 |
Elashoff, J. D. (2007). nQuery Advisor. Version 7.0 User Guide, Statistical Solutions, Los Angeles.
|
15 |
Steinijans, V. W., Sauter, R., Jonkman, J. H., Schulz, H., Stricker, H. and Blume, H. (1989). Bioequivalence studies: Single vs multiple dose, International Journal of Clinical Pharmacology, Therapy and Toxicology, 27, 261-266.
|
16 |
Berger, R. L. and Hsu, J. C. (1996). Bioequivalence trials, intersection-union tests and equivalence confidence sets, Statistical Science, 11, 283-319.
DOI
ScienceOn
|
17 |
Brown, L. D., Hwang, J. T. and Munk, A. (1997). An unbiased test for the bioequivalence problem, The annals of Statistics, 25, 2345-2367.
DOI
|
18 |
Bruno, R., Washington, C. B., Lu, J., Lieberman, G., Banken, L. and Klein, P. (2005). Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer, Cancer Chemother Pharmacol, 56, 361-369.
DOI
ScienceOn
|